Inositol vs Metformin for PCOS (Now PMOS): What the Trials Show

Your doctor offered metformin. The internet told you inositol does the same thing without the stomach problems. Both of those can't be casually true, and the gap between them is where most people get stuck for months.

We went through the head-to-head trials and the two most recent pooled analyses. The honest summary is less tidy than the supplement blogs suggest: on most outcomes these two are statistically indistinguishable, metformin beats inositol on two specific things, and inositol's famous tolerability edge is real but softer than it's usually sold. None of that makes inositol a bad choice. It just means the choice depends on what you're actually treating.

PCOS is now PMOS — Polyendocrine Metabolic Ovarian Syndrome, after the Lancet consensus renamed it in May 2026. Both names appear here because both are still in use.

Which one works better?

For the outcomes most people care about, the answer is: neither, measurably.

The systematic review that informed the 2023 International Evidence-based PCOS Guidelines pooled 10 randomized trials comparing myo-inositol directly against metformin — 709 women in total. Ovulation showed no significant difference (OR 1.28, 95% CI 0.59–2.77). Neither did menstrual regularity (OR 1.85, CI 0.68–5.01), BMI (MD 0.03), or total testosterone (MD 4.69, CI −2.55–11.93). Certainty ranged from moderate down to very low.

An umbrella review published in February 2026 — 13 meta-analyses, 85 outcome measures — landed in the same place. Ovulation favored inositol but missed significance (RR 1.33, CI 0.99–1.77, p=0.05, moderate certainty). HOMA-IR, total testosterone, and BMI all showed no meaningful separation.

Two outcomes did separate, and both favored metformin. Hirsutism scores improved more on metformin (MD 2.42, CI 1.52–3.44) and so did waist-hip ratio (MD 0.04, CI 0.01–0.06). Certainty was low for both, so hold them loosely — but they're the only clear winners on the board, and they point the same direction.

This is why the guidelines read the way they do. Metformin is recommended first-line for metabolic and anthropometric outcomes, particularly at BMI ≥25 (and the Asian cutoff is 23, not 25). Inositol is positioned as a reasonable alternative for women who can't tolerate metformin. The guideline authors' own words: the evidence for inositol is "limited and inconclusive."

We'd add the obvious counterweight. "No significant difference" across ten trials is not evidence that inositol fails — it's evidence that a supplement with a mild side-effect profile is holding its own against a prescription drug. That's a genuinely useful finding. It's just not the finding that "inositol beats metformin" implies.

Which one works faster?

Similar timelines, different failure modes.

Both are usually evaluated at 3 to 6 months, and both need roughly 8–12 weeks before cycle changes are fair to judge. Some people notice cravings and energy shifting inside the first few weeks on inositol, but that's not the outcome either drug is really being measured on. For anything involving skin, hair, or ovulation, the 90-day rule applies to both: follicles and hair cycles don't move faster because you're impatient.

The real-world difference isn't onset speed. It's whether you're still taking it at week 12. Metformin's gastrointestinal side effects tend to hit early, which means the people who quit usually quit before the drug has had a chance to demonstrate anything. A treatment you abandoned at week two has an effectiveness of zero, regardless of what the trials say.

Side effects: the actual difference

This is inositol's strongest claim, and it mostly holds.

Pooled across six trials, myo-inositol produced dramatically fewer gastrointestinal adverse events than metformin (OR 0.09, CI 0.02–0.37, moderate certainty). Nausea, diarrhea, cramping, bloating — the metformin starter-pack.

Here's the part almost nobody quotes. When the same reviewers restricted the analysis to the studies at low risk of bias, that difference disappeared. That doesn't erase the finding, and it doesn't match anyone's clinical experience of metformin, but it does mean the effect size is probably smaller than the headline number. Metformin's side effects are also typically mild, self-limiting, and substantially reduced by extended-release formulations and slow dose titration — which is standard practice and often skipped in trials.

Can you take inositol and metformin together?

Yes, and there's now decent trial evidence that the combination beats metformin alone.

A Phase III double-blind randomized trial published in 2024 tested a fixed-dose combination — metformin SR 500 mg plus myo-inositol 600 mg twice daily — against metformin SR 500 mg twice daily in 196 women over 24 weeks. Insulin resistance improved in 75% of the combination group versus 60.7% on metformin alone (p=0.049), with better menstrual-frequency improvement as well. Safety was comparable; nobody discontinued for an adverse event.

The margin is modest and the p-value is sitting right on the line. But the direction is consistent, the safety signal is clean, and it makes mechanistic sense — the two work on insulin signaling by different routes rather than competing.

Practical notes from the trial protocols: metformin is taken with meals, inositol between them. Inositol doses in PMOS research are typically 2 g twice daily at a 40:1 myo-to-D-chiro ratio, well above the 600 mg used in the fixed-dose product. Adding a supplement to a prescription is a conversation to have with whoever prescribed it — not because it's dangerous, but because your metformin dose may need adjusting.

Where the internet's favorite number comes from

If you've read more than three articles on this, you've seen it: myo plus D-chiro inositol produced a 46.7% pregnancy rate versus 11.2% on metformin.

It's a real number from a real study — 128 women, three months, published in a small specialty journal. It's also a single trial with a startlingly low metformin arm, and it sits inside a pooled body of evidence that finds no significant fertility difference between the two. When one study disagrees this loudly with ten others, the ten usually win.

There's a fresher and less convenient data point in the same territory. In September 2025, JAMA published the MYPP trial: 464 women with PMOS across 13 Dutch hospitals, myo-inositol 4 g daily during pregnancy versus placebo. The composite outcome of preeclampsia, gestational diabetes, or preterm birth occurred in 25% of the inositol group and 26.8% of the placebo group. No benefit. The authors concluded it shouldn't be recommended in pregnancy.

That trial tested inositol during pregnancy, not for conceiving — it doesn't undercut inositol's cycle-regulation evidence. We're including it because it's the largest recent trial in this space and it came back negative, and a comparison that only reports the flattering studies isn't a comparison.

Which one suits you

The pooled data says these are close. That makes the tiebreakers personal, and they're reasonably clear:

Metformin fits better when insulin resistance is well-documented, BMI is above the cutoff, there's prediabetes or a strong family history of type 2 diabetes, or hirsutism and central weight are your primary complaints — the two outcomes it won.

Inositol fits better when you've tried metformin and couldn't stay on it, your metabolic markers are borderline rather than frank, you're in a lean phenotype where metformin's anthropometric edge matters less, or you want to start something while waiting on an appointment.

Both together is worth raising if you're already on metformin, tolerating it, and not getting enough movement on cycles or insulin markers.

One honest caveat on inositol: somewhere between 28% and 38% of people don't respond to it at all, often for reasons involving gut absorption or the wrong driver. If three months at a proper dose changes nothing, that's information, not failure.

The thing underneath all of this is that "PMOS" describes several different metabolic situations wearing one name, and the right pick depends on which one is yours. Insulin resistance drives many cases but not all — androgen-dominant and ovulation-driven presentations respond differently, and neither drug is aimed at them specifically.

If you don't know which driver is yours, that's the more useful question to answer first. Our free assessment maps your symptoms and labs against the recognized PMOS phenotypes in about five minutes — so the inositol-versus-metformin conversation with your doctor starts from your actual pattern instead of a coin flip.

---

We inform; we don't diagnose or prescribe. Metformin is a prescription medication and inositol interacts with how you manage blood sugar — decisions about either belong with your clinician.

Sources: Fitz et al., Inositol for Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis to Inform the 2023 Update of the International Evidence-based PCOS Guidelines, JCEM 2024 (PMC11099481) · Effects of inositol in women with polycystic ovary syndrome: an umbrella review of meta-analyses from randomized controlled trials, Frontiers in Endocrinology, February 2026 · A Phase III, Double-Blind, Randomized, Multicenter Clinical Trial of a Fixed-Dose Combination of Metformin Hydrochloride and Myo-Inositol Compared to Metformin in PCOS, 2024 (PMC11725314) · MYPP trial, JAMA, September 30, 2025 · 2023 International Evidence-based Guideline for the Assessment and Management of PCOS (Monash).